These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38885690)

  • 21. European activities in radiation protection in medicine.
    Simeonov G
    Radiat Prot Dosimetry; 2015 Jul; 165(1-4):34-8. PubMed ID: 25870434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines.
    Outterson K
    Health Aff (Millwood); 2021 Nov; 40(11):1758-1765. PubMed ID: 34724432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges.
    Vella Bonanno P; Cassar V; Godman B
    Front Pharmacol; 2021; 12():666405. PubMed ID: 34867312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct access and patient/client self-referral to physiotherapy: a review of contemporary practice within the European Union.
    Bury TJ; Stokes EK
    Physiotherapy; 2013 Dec; 99(4):285-91. PubMed ID: 23537881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Where we are in the fight against Antimicrobial Resistance and Healthcare-Associated Infections. The opinion of the stakeholders of the European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI).
    Fabbro E; Arnau Sánchez J; Del Pilar López Acuña M; Hukelová H; Alcaraz Quiñonero M; Pantosti A; Busani L
    Ann Ist Super Sanita; 2022; 58(3):204-212. PubMed ID: 36128970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The European Union and Public Health Emergencies: Expert Opinions on the Management of the First Wave of the COVID-19 Pandemic and Suggestions for Future Emergencies.
    Gontariuk M; Krafft T; Rehbock C; Townend D; Van der Auwermeulen L; Pilot E
    Front Public Health; 2021; 9():698995. PubMed ID: 34490183
    [No Abstract]   [Full Text] [Related]  

  • 27. A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development.
    Bhavnani SM; Krause KM; Ambrose PG
    Open Forum Infect Dis; 2020 Jul; 7(7):ofaa083. PubMed ID: 32667365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transposition and implementation of EU rare disease policy in Eastern Europe.
    Pejcic AV; Iskrov G; Raycheva R; Stefanov R; Jakovljevic MM
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):557-566. PubMed ID: 28975845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fighting Antimicrobial Resistance and Healthcare-Associated Infections in EU-JAMRAI: The One-Health Response from Italy.
    Busani L; Creti R; Fabbro E; Prestinaci F; Pantosti A; Marella AM; Brusaferro S; Sabbatucci M
    Chemotherapy; 2024; 69(1):56-64. PubMed ID: 37673044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
    Årdal C; Lacotte Y; Ploy MC
    Clin Infect Dis; 2020 Nov; 71(8):1994-1999. PubMed ID: 32060511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. R&D incentives for neglected diseases.
    Dimitri N
    PLoS One; 2012; 7(12):e50835. PubMed ID: 23284648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Environmental and social responsibility of companies cross EU countries - Panel data analysis.
    Lončar D; Paunković J; Jovanović V; Krstić V
    Sci Total Environ; 2019 Mar; 657():287-296. PubMed ID: 30543978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Eurocode International Blood Labeling System" enables unique identification of all biological products from human origin in accordance with the European Directive 2004/23/EC.
    Knels R; Mönig HJ; Wittmann G; von Versen R; Pruss A
    Cell Tissue Bank; 2010 Nov; 11(4):345-52. PubMed ID: 20563859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PATENTING OF MEDICINES IN UKRAINE THROUGH THE PRISM OF THE ASSOCIATION AGREEMENT WITH THE EU AND THE TRIPS AGREEMENT: IMPROVEMENT IN MEDICAL AND ADMINISTRATIVE REGULATIONS.
    Deshko L; Ivasyn O; Gurzhii T; Novikova T; Radyshevska O
    Georgian Med News; 2019 Mar; (288):154-158. PubMed ID: 31101796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine market access pathways in the EU27 and the United Kingdom - analysis and recommendations for improvements.
    Laigle V; Postma MJ; Pavlovic M; Cadeddu C; Beck E; Kapusniak A; Toumi M
    Vaccine; 2021 Sep; 39(39):5706-5718. PubMed ID: 34404557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-sector cooperation in health-enhancing physical activity policymaking: more potential than achievements?
    Hämäläinen RM; Aro AR; Lau CJ; Rus D; Cori L; Syed AM;
    Health Res Policy Syst; 2016 Apr; 14(1):33. PubMed ID: 27129850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral healthcare systems in the extended European union.
    Widström E; Eaton KA
    Oral Health Prev Dent; 2004; 2(3):155-94. PubMed ID: 15641621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Policy on palliative care in the WHO European region: an overview of progress since the Council of Europe's (2003) recommendation 24.
    Woitha K; Carrasco JM; Clark D; Lynch T; Garralda E; Martin-Moreno JM; Centeno C
    Eur J Public Health; 2016 Apr; 26(2):230-5. PubMed ID: 26545804
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.